Cosmos Health Inc Dossier
Qualitative Analysis
Business overview
Cosmos Health Inc. (NASDAQ: COSM) is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. The company operates across several core segments, including wholesale pharmaceutical distribution, proprietary brand manufacturing, and contract manufacturing services. Its proprietary portfolio features well-known brands such as Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub. Through its subsidiary Cana Laboratories S.A., which operates an EU-GMP-licensed and EMA-certified facility, Cosmos Health manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices. The company's wholesale logistics operations are anchored by CosmoFarm, serving an extensive and growing pharmacy network in Europe.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launching the '18 Series' science-driven nutraceutical platform (including Noor18, Liv18, Cur18, Fort18, and Oliv18) directly to consumers in the United States, with plans to expand into retail channels.
Expected impact: Projected to generate annualized revenues exceeding $22.7 million with approximately $17.0 million in implied gross profit (at ~75% gross margins).
Entering the global skincare market by launching a premium, Korean-developed collagen-based skincare line directly to consumers in the United States.
Expected impact: Aims to capture a share of the high-margin beauty market to diversify the portfolio beyond traditional healthcare roots and improve overall margins.
Leveraging existing intellectual property and manufacturing infrastructure to launch a veterinary version of its C-Scrub Wash 4% antimicrobial product.
Expected impact: Provides access to a recurring revenue opportunity in the global animal health market, which is projected to reach $156 billion by 2033.
Securing long-term contract manufacturing agreements at Cana Laboratories' EU-GMP-licensed, EMA-certified facility to produce high-demand medicines and dermatological products.
Expected impact: Includes a 5-year agreement with Pharmex S.A. to produce 2.86 million units of three pharmaceutical products, driving higher capacity utilization and operational leverage.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquiring 100% of a fully licensed GMP pharmaceutical manufacturer with an approximately $24 million asset base to deepen vertical integration, expand production capacity, and broaden the in-house product portfolio.
Financial impact: Expected to be immediately accretive, adding approximately $6.7 million in average annual revenue and $3.2 million in average annual gross profit.
Acquiring an extensive pharmacy distribution network serving the Greek market for almost 40 years to expand the distribution footprint and integrate with CosmoFarm's automated logistics.
Financial impact: The network currently generates approximately $11.5 million (€10 million) in annual gross revenue.
Acquisition of ownership of an international patent application to support next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development, expanding nanotechnology investment initiatives.
Financial impact: Strengthens the proprietary IP portfolio and transitions the company from AI-enabled discovery to proprietary product development.
Strategic Partnerships
Cana Laboratories entered into an advisory agreement with the EIB to pursue a strategic R&D financing program of up to €25 million (supporting a €50 million R&D program).
Terms: Advisory agreement to align R&D initiatives with EIB evaluation criteria for potential future funding.
Cana Laboratories will manufacture three pharmaceutical products at its EU-GMP-licensed facility, strengthening its contract manufacturing division.
Terms: Production of approximately 2.86 million units over the five-year term.